A phase III, randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a cdk4/6 inhibitor, in patients with estrogen receptor-positive, her2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy

PI: Giulia Bianchi

A Phase III, 1:1, randomized, open-label study to evaluate the efficacy and safety of Giredestrant versus Fulvestrant, both in combination with a CDK4/6 inhibitor, in patients with HER2-negative, estrogen receptor-positive, advanced breast cancer that has been resistant to prior adjuvant endocrine therapy. 

Patients with ER-positive, HER2-negative advanced or metastatic breast cancer that has relapsed during or up to 1 year after adjuvant hormone therapy and who are about to start their first treatment for advanced breast cancer are eligible to participate in the protocol.